1. Kalashnikova M. F., Belousov D. Yu., Cheberda A. E., Fadeev V. V. Farmakoekonomicheskii analiz primeneniya sovremennykh peroral'nykh sakharosnizhayushchikh preparatov pri nedostatochnom glikemicheskom kontrole na metformine. Kachestvennaya klinicheskaya praktika. 2019;(1):27–52. [Kalashnikova MF, Belousov DYu, Cheberda AE, Fadeev VV. Pharmacoeconomic analysis of modern oral hypoglycemic agents with inadequate glycemic control on metformin. Kachestvennaya klinicheskaya praktika. 2019;(1):27–52. (In Russ).]. doi: 10.24411/2588-0519-2019-10062
2. Zyryanov S. K., D'yakov I. N. Kliniko-ekonomicheskaya effektivnost' primeneniya preparata dapagliflozin u patsientov s sakharnym diabetom 2-go tipa v usloviyakh zdravookhraneniya Rossiiskoi Federatsii. Kachestvennaya klinicheskaya praktika. 2019;(4):23–32. [Zyryanov SK, Dyakov IN. Clinical and economic efficiency of treatment with dapagliflozin of patients with type 2 diabetes mellitus in Russian health care conditions. Kachestvennaya klinicheskaya praktika. 2019;(4):23–32. (In Russ).]. doi: 10.24411/2588-0519-2019-10062
3. Kolbin A. S., Kurylev A. A., Balykina Yu. E., Proskurin M. A., Karpov O. I. Ekonomicheskaya otsenka intensifikatsii insulinoterapii dlya effektivnogo i bezopasnogo kontrolya sakharnogo diabeta 2-go tipa. Kachestvennaya klinicheskaya praktika. 2019;(2):25–35. [Kolbin AS, Kurilev AA, Balikina YuE, Proskurin MA, Karpov OI. Economic evaluation of insulin therapy intensification for effective and safe control of Diabetes Mellitus type 2. Kachestvennaya klinicheskaya praktika. 2019;(2):25–35. (In Russ).]. doi: 10.24411/2588-0519-2019-10070
4. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–9. doi: 10.1016/S0140-6736(18)32590-X
5. Palmer SC, Tendal B, Mustafa RA et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573